pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
9679K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12802T | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12802T | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10894J | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10894J | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10894J | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13069W | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12430F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12430F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12430F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12430F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12430F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12430F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10511F | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10511F | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11482H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11482H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11482H | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8741C | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13727L | abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Subsequent continuing treatment | 14604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9459W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10774C | ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10774C | ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10774C | ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10774C | ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12085C | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12085C | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12085C | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9086F | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9086F | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9086F | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9086F | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8637N | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8637N | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8637N | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
8637N | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11218K | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
11218K | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
10901R | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13208E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13208E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13208E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13208E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13294Q | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Continuing treatment | 14154 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11325C | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11325C | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13210G | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
13210G | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
13210G | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11730J | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |